Samantha Noteboom
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosis.
Journal: Journal of neurology
Published: February 19, 2026
Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 26, 2025
In vivo evidence for cell body loss in cortical lesions in people with multiple sclerosis.
Journal: Annals of clinical and translational neurology
Published: September 28, 2024
Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex.
Journal: Annals of clinical and translational neurology
Published: August 15, 2024
Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 14, 2024
9-HODE associates with thalamic atrophy and predicts white matter damage in multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: May 24, 2024
Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
Journal: Journal of neurology
Published: March 19, 2024
Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
Journal: Journal of neurology
Published: February 29, 2024
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 18, 2024
The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
Journal: Journal of neurology
Published: December 08, 2023
Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
Journal: Multiple sclerosis and related disorders
Published: November 29, 2023
Last Updated: 09/26/2026